MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
19 May 2022 - 8:00PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will ring the opening bell at the Nasdaq stock
exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq
MarketSite at Times Square.
The ceremony will begin at approximately 9:15 am ET and can be
viewed live from the Events & Presentations section of the
Company’s website at
https://investors.mannkindcorp.com/events-and-presentations.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development
and commercialization of inhaled therapeutic products for patients
with endocrine and orphan lung diseases. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company’s first FDA-approved product and the only inhaled ultra
rapid-acting mealtime insulin in the United States, where it is
available by prescription from pharmacies nationwide. Afrezza is
also available by prescription in Brazil, where it is
commercialized by the Company’s partner, Biomm SA. MannKind was
established in 1991, and is located in Danbury, Conn., and Westlake
Village, Calif. The Company also employs field sales and medical
representatives across the U.S. Please visit mannkindcorp.com to
learn more.
MANNKIND CONTACTS:Christie Iacangelo, Corporate
Communications(818) 292-3500Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations(818) 661-5000Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2024 to May 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From May 2023 to May 2024